Nantahala Capital Management LLC acquired a new position in shares of Savara Inc. (NASDAQ:SVRA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 6,976,810 shares of the company's stock, valued at approximately $42,977,150. Savara comprises about 0.0% of Nantahala Capital Management LLC's portfolio, making the stock its 8th biggest position. Nantahala Capital Management LLC owned about 3.40% of Savara as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Prudential Financial Inc. purchased a new position in shares of Savara in the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets increased its position in shares of Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP purchased a new stake in Savara during the 2nd quarter valued at $33,000. Russell Investments Group Ltd. raised its holdings in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after buying an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in Savara in the third quarter worth $44,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
SVRA has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a research note on Friday, July 17th. Wall Street Zen lowered shares of Savara from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.14.
Get Our Latest Stock Analysis on SVRA
Savara Trading Down 4.2%
SVRA opened at $5.26 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. The stock's 50 day moving average price is $5.70 and its 200-day moving average price is $5.48. Savara Inc. has a one year low of $3.19 and a one year high of $7.01. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -9.07 and a beta of 0.29.
Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). On average, equities analysts forecast that Savara Inc. will post -0.62 EPS for the current year.
Savara Profile
(
Free Report)
Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Featured Articles
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
